In this episode, Martin examines Meta’s decision to sell AI compute capacity and discusses whether it signals growing overcapacity in the AI infrastructure market. He explores the implications for cloud providers, chipmakers, and AI-related companies, and explains how these developments could affect the next phase of investment in the sector.

In this episode, Martin questions the expectations surrounding SpaceX’s potential valuation by comparing its growth prospects with the broader space industry and government spending. He also turns to the semiconductor sector, discussing recent movement in memory stocks and what changing demand and market conditions could mean for the industry.

In this episode, Martin discusses Meta’s move into the AI cloud business and examines how increased competition could affect existing players in AI infrastructure and computing. He identifies the stocks and companies he believes could face the most pressure, then explores photonic computing and its potential role in the next generation of AI hardware.

In this episode, Martin highlights what he sees as a particularly attractive opportunity in the market and explains the reasoning behind his view. He also analyzes Take-Two, Amgen, Bloom Energy (BE), and Marvell Technology (MRVL), examining their valuations, growth prospects, and the factors shaping his outlook on each stock.

In this episode, Martin examines why repeatedly buying market dips can fail and discusses the conditions that make the strategy particularly risky. He also looks back at the trade that helped launch his career, explaining the opportunity he identified, how he approached the position, and the impact it had on his development as an investor.

In this episode, Martin explains why he believes AI has already demonstrated its ability to generate profits and discusses what that means for investors looking at the sector. He revisits Micron and the semiconductor market, analyzes AbbVie from a pharmaceutical perspective, and takes a closer look at Cerebras (CBRS) and its position within the growing AI infrastructure industry.

In this episode, Martin revisits his short thesis on Sellas (SLS) and explains why recent developments are causing him to reconsider parts of the trade. He reviews the factors influencing his updated outlook and looks back at some of his best short calls, discussing the setups and analysis behind those positions.

In this episode, Martin reviews his current short positions and explains the reasoning behind his bearish trades. He takes a closer look at Rocket Lab (RKLB), examines Evommune from a biotech perspective, and revisits Micron (MU) as he assesses valuations and opportunities across the semiconductor market.

In this episode, Martin highlights a common mistake he believes investors make when evaluating biotech companies and explains how it can affect valuations and investment decisions. He then lays out his short thesis on Sellas (SLS), examining the company’s pipeline and clinical outlook, before turning to Tenax Therapeutics and its potential within the biotech sector.

In this episode, Martin speaks with a biotech trader about his high-risk approach to investing and the positions putting his portfolio at risk. He breaks down the dangers of concentrated biotech bets, discusses position sizing and risk management, and offers his perspective on how the trader could approach his investments differently.